Why Corticosteroid Injections Are Not as Benign as You’ve Been Told

Cortisone injections are described, routinely, as simple pain shots. Quick visit. Temporary relief. Manageable risk. For patients dealing with knee pain, hip arthritis, shoulder irritation, elbow tendon pain, or spine inflammation, that framing sounds reasonable.

It is incomplete.

What happens to the tissue after the pain goes quiet matters. For patients who have received one injection, or several, understanding the documented effects of corticosteroid exposure is part of making an informed decision about what comes next.

This article covers six tissue-level effects of corticosteroid injections that are established in the medical literature and rarely explained in full during a clinical visit.

It is authored by Dr. Tammy J. Penhollow, DO, a dual board-certified physician in Anesthesiology and Pain Medicine, Stanford fellowship-trained interventional specialist, and founder of Precision Regenerative Medicine in Scottsdale, Arizona. Dr. Penhollow has practiced exclusively in cash-pay regenerative spine and joint medicine since 2015 and does not use corticosteroids in her clinical practice.

Why Cortisone Is Still Used

Corticosteroids reduce inflammation. They can calm a swollen joint, quiet a painful bursa, and allow someone to move through an acute flare. In selected situations, with appropriate timing and clinical judgment, they can be a useful tool.

The problem is not the medication. The problem is the framing. A cortisone injection is not a reset. It does not repair cartilage, rebuild tendon collagen, address mechanical instability, correct metabolic dysfunction, or treat the underlying diagnosis. It quiets a signal. The tissue problem it is masking continues.

Patients who receive repeated injections over months or years, often in the same joint or across multiple sites, are accumulating a different risk profile than the language around a single shot typically suggests.

Six Corticosteroid Effects Patients Should Understand

1. Direct Cartilage Toxicity (Chondrotoxicity)

Cartilage is the load-bearing surface that allows bones to move smoothly inside a joint. It has limited blood supply and limited capacity for self-repair. Any substance introduced into a joint should be evaluated for its effect on chondrocytes, the cells that maintain cartilage structure.

Corticosteroids can be chondrotoxic under certain conditions. In vitro and in vivo research has documented dose-dependent and frequency-dependent effects on chondrocyte viability and extracellular matrix integrity. This is particularly relevant for patients who already have cartilage thinning, early or moderate osteoarthritis, or a history of repeated intra-articular injections.

Pain relief and joint protection are not the same outcome. A patient can feel better after an injection while the structural environment of the joint continues to deteriorate. That dissociation between subjective improvement and objective tissue status is what makes repeated corticosteroid use in arthritic joints a clinical concern, not a minor footnote.

2. Tendon Weakening and Rupture Risk

Tendons transmit force from muscle to bone. They are under load during nearly every functional movement. They are also sensitive to peri-tendinous and intra-tendinous steroid exposure.

Corticosteroids can disrupt tendon collagen organization, reduce tensile strength, and create a window during which the tendon feels less painful but is structurally more vulnerable. Patients who return to full loading after injection, which is common because the pain signal has quieted, may be placing significant force through tissue that has not structurally recovered.

Tendon areas that carry documented risk with steroid exposure include the Achilles, patellar, rotator cuff, biceps, and the common extensor and flexor tendons of the elbow. Rupture in these locations is not a minor complication. It changes strength, function, sport participation, and in some patients, independence.

3. Steroid-Induced Bone Loss

Bone is metabolically active tissue. It responds continuously to hormonal signals, mechanical loading, nutrition, and medication exposure. Corticosteroids interfere with bone metabolism by suppressing osteoblast function, accelerating osteoclast activity, and impairing calcium absorption. The net effect is a reduction in bone formation relative to bone resorption.

For patients with existing low bone density, inflammatory disease, postmenopausal bone loss, or cumulative steroid exposure from other medical care, a series of joint injections is not happening in isolation. The medication moves beyond the injection site. Systemic effects are dose-dependent and frequency-dependent, but they are real.

Bone quality affects joint stability, arthritis progression, healing potential, and fracture risk. It is part of the full tissue picture that should inform any injection decision.

4. Hyperglycemia and Blood Sugar Disruption

Corticosteroids reliably elevate blood glucose. The mechanism is well established: steroids promote gluconeogenesis in the liver, reduce peripheral glucose uptake, and impair insulin sensitivity. For most patients with normal glucose regulation, the effect is transient. For patients with diabetes, prediabetes, insulin resistance, or a history of glucose instability, even a single joint injection can produce a clinically significant spike.

This is not a theoretical concern. Endocrinology literature documents post-injection hyperglycemia following intra-articular corticosteroid injections, including in patients who did not present with active diabetes. Blood sugar monitoring after injection is appropriate for at-risk patients, and the glucose effect should be discussed before the injection is administered, not discovered afterward.

5. Adrenal Axis Suppression

The hypothalamic-pituitary-adrenal (HPA) axis regulates endogenous cortisol production, which governs stress response, immune activity, inflammatory control, and energy regulation. Exogenous corticosteroids signal the HPA axis to reduce its own output. In most patients, this suppression is temporary and subclinical. In some patients, particularly those receiving repeated injections across multiple sites or over a short time interval, the suppression is meaningful.

Symptoms of adrenal axis suppression include fatigue, mood changes, poor stress tolerance, low energy, and feeling systemically off in a way that patients often attribute to sleep, pain, or aging. These symptoms are not obviously connected to an injection received weeks or months prior.

A patient with steroid exposures across the knee, shoulder, hip, elbow, and spine within a single calendar year carries a different HPA burden than a patient who received one isolated injection several years ago. That distinction matters in the clinical evaluation.

6. Local Tissue Atrophy

Corticosteroids can produce localized tissue atrophy at and around the injection site. Skin may thin. Subcutaneous fat may diminish. A visible depression or contour change may appear. Skin depigmentation is possible, particularly in patients with darker skin tones. These changes typically appear weeks after the injection and are often not connected by the patient to the procedure.

Local atrophy is more likely with superficial injections, high steroid concentration, or repeated injections in the same anatomical area. For some patients, these changes are lasting. They are a reminder that a corticosteroid injection is still a medical intervention with a local tissue footprint, not simply a pain management tool with contained effects.

What a Regenerative Evaluation Considers After Steroid Exposure

Patients who present to Precision Regenerative Medicine with a history of corticosteroid injections are not disqualified from regenerative care. They do require a more detailed tissue assessment before any plan is built.

Dr. Penhollow’s evaluation, informed by her interventional fellowship training and image-guided procedural precision, covers:

• Date, location, dose, and number of prior steroid injections
• Duration of relief after each injection and whether relief shortened over time
• Any blood sugar response, skin changes, or local tissue changes observed after injection
• Current cartilage status by imaging and clinical exam
• Tendon quality at treated and adjacent sites
• Bone density status when relevant to the clinical picture
• HPA axis considerations in patients with multiple or recent steroid exposures
• Timing, because recent steroid exposure can influence the tissue environment and the sequencing of any regenerative intervention

Recent steroid exposure does not automatically delay care. It does change how the tissue is assessed and how the treatment plan is sequenced. The goal is to build a biological plan that works with the tissue environment as it currently exists, not despite it.

Frequently Asked Questions